Next Article in Journal
Evaluation of Gait Parameters on Subjects with Hallux Limitus Using an Optogait Sensor System: A Case–Control Study
Next Article in Special Issue
Prevalence of Poor Sleep Quality and Associated Factors in Individuals with Rheumatoid Arthritis: A Cross-Sectional Study
Previous Article in Journal
Spindle Cell Rhabdomyosarcoma of the Inguinal Region Mimicking a Complicated Hernia in the Adult—An Unexpected Finding
Previous Article in Special Issue
Long-Term Retention Rate of Tofacitinib in Rheumatoid Arthritis: An Italian Multicenter Retrospective Cohort Study
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Medicina
Volume 59
Issue 9
10.3390/medicina59091517
Review Report
medicina-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Case Report
Peer-Review Record

Safe and Efficient Use of Tocilizumab in Rheumatoid Arthritis Patient on Maintenance Hemodialysis: A Case Report

Medicina 2023, 59(9), 1517; https://doi.org/10.3390/medicina59091517
by Paula Kilić 1,*, Lucija Ikić 2, Miroslav Mayer 3,4, Marinko Artuković 1, Ksenija Maštrović Radončić 5 and Marina Ikić Matijašević 1,3,*
Reviewer 1:
Marino Paroli
Reviewer 2:
Anca Bobirca
Medicina 2023, 59(9), 1517; https://doi.org/10.3390/medicina59091517
Submission received: 29 July 2023 / Revised: 15 August 2023 / Accepted: 21 August 2023 / Published: 23 August 2023
(This article belongs to the Special Issue Recent Advances in Rheumatoid Arthritis)

Round 1

Reviewer 1 Report

The authors describe a clinical case of rheumatoid arthritis associated with end-stage renal failure successfully treated with tocilizumab.

The work is interesting. however, it needs some clarifications:

1) Tocilizumab was administered weekly after hemodialysis session. However, the patient was undergoing hemodialysis three times a week. Could this have reduced the blood concentration of tocilizumab? Do the authors believe that more frequent administrations of tocilizumab may be more effective in patients on hemodialysis?
2) Treatment with tocilizumab is associated with increased infectious risk. Hemodialysis patients are generally immunocompromised. What is the infectious risk in treating such a patient with tocilizumab?
3) The patient was APCA positive. Could treatment with abatacept, which is less risky for infection, be an alternative? What about possible treatment with TNFi?
4) Some JAKi such as upadacitinib have no significant impact on renal function. Can they be in the authors' opinion an additional alternative to tocilizumab?

English needs only minor changes

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Reviewer 2 Report

the authors must restructure the abstract ( maybe paraphrasing)

there are needed extensive english corrections

the subject is very important, kind of unmeet needs in dailly Rheumatology  practice 

I recommend to authors to realize a graphical image in the intoduction chapter with the glomerulofilration / hemodialysis 

I thought that the article is not suitable for  Life, but I verrified the literature and I was really surprised of the limited data on this topic ( more from COVID era- the authors cited these article) , I encourage the authors to restructure the article . 

more Discussion about all the antirheumatic drugs use  in hemodialysized patients 

 

 

-

Author Response

Please see the attachment.

Author Response File: Author Response.docx

Round 2

Reviewer 2 Report

the authors answerred according to Reviewers querries. 

 

Back to TopTop